Merus Labs International Company Profile (NASDAQ:MSLI)

Analyst Ratings

Consensus Ratings for Merus Labs International (NASDAQ:MSLI) (?)
Ratings Breakdown: 2 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $4.61 (249.57% upside)

Analysts' Ratings History for Merus Labs International (NASDAQ:MSLI)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016WedbushReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016GuggenheimReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Citigroup Inc.Reiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2016ScotiabankReiterated RatingSector Perform$2.75 -> $2.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016Paradigm CapitalReiterated RatingBuy$2.10 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016MackieReiterated RatingHold$1.90 -> $2.30View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016Dundee SecuritiesReiterated RatingBuy$3.50 -> $3.60View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/30/2015Royal Bank Of CanadaReiterated RatingSector Outperform$2.90View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/30/2015CIBCInitiated CoverageSector Outperform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2015TD SecuritiesInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2015LB SecuritiesReiterated RatingBuy$3.50 -> $3.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/18/2014Laurentian Bank of CanadaInitiated CoverageBuy$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Merus Labs International (NASDAQ:MSLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
12/18/2014($0.01)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Merus Labs International (NASDAQ:MSLI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.00$0.06$0.03
Q2 20165($0.01)$0.07$0.02
Q3 20163$0.01$0.06$0.04
Q4 20162$0.01$0.02$0.02
Q1 20172$0.01$0.02$0.02
Q2 20172$0.01$0.02$0.02
Q3 20173$0.01$0.02$0.02
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Merus Labs International (NASDAQ:MSLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Merus Labs International (NASDAQ:MSLI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Merus Labs International (NASDAQ:MSLI)
DateHeadline
07/04/16 07:51 AMMerus Labs Appoints Two Senior Executives - [at noodls] - 718dfb10-f0e9-4420-88ff-e391a368de93.pdf Merus Labs Appoints Two New Senior Executives TORONTO, ONTARIO - June 30, 2016 - Merus Labs International Inc. ("Merus" or the "Company") (TSX: ...
07/04/16 06:00 AMMerus Announces Reduced Leverage and Provides Business Update - [PR Newswire] - TORONTO, July 4, 2016 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce that it has made the first of its regularly scheduled quarterly principal repayments under its new credit facility and to provide a general business update. On June 30, 2016, Merus made an initial payment on its term debt of approximately $8 million. Merus is required to make quarterly principal payments under this facility, which will result in continual deleveraging and reduced interest expense. Additionally, the facility provides for decreased interest rates as the Company`s leverage decreases, an event we anticipate will lower our current annual rate from 4.5% to 4.0% by the end of 2016. The Company's net debt currently stands at approximately $150 million. A natural hedge exists as the majority of Merus revenue, expenses and debt are Euro denominated.
06/30/16 03:00 PMMerus Labs Appoints Two New Senior Executives - [PR Newswire] - TORONTO, June 30, 2016 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce two key additions to its executive leadership team effective July 1, 2016. Dr. Michael Bumby is appointed Chief Financial Officer (CFO) succeeding Mr. Andrew Patient who has decided to leave the Company to pursue other opportunities. Mr. Patient will remain with Merus Labs for a period of time to ensure a smooth transition.
05/26/16 10:49 AMMerus Labs International Inc. (NASDAQ:MSLI) Reports Yearly Sales Estimate At $93.125 - Investor Newswire - Merus Labs International Inc. (NASDAQ:MSLI) Reports Yearly Sales Estimate At $93.125Investor NewswireAs many as 2 analysts reported that average annual sales estimate for Merus Labs International Inc. (NASDAQ:MSLI) stands at $93.125 and the median is $93.125 for the period closed 3. The lowest sales forecast is $86.8 and the highest sales estimate is ...and more »
05/18/16 03:24 PMMerus Labs International Inc. Announces Deemed Exercise of Special Warrants - [PR Newswire] - TORONTO, May 18, 2016 /PRNewswire/ - Merus Labs International Inc. (" Merus " or the " Company ") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today the deemed exercise of the Company's ...
05/11/16 04:56 PMMerus Labs reports 2Q loss -
05/11/16 03:00 PMMerus Labs Reports Fiscal Q2 2016 Results - [PR Newswire] - TORONTO, May 11, 2016 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] today announced its financial results for its second quarter of fiscal year 2016. For fiscal Q2 2016, the Company incurred a net loss of $3.4 million compared to a net income of $1.8 million for the prior year period.
04/04/16 11:00 AMMerus Announces Re-Election of Directors - [at noodls] - 7a1bf2ab-390a-403d-8720-94cd108a5d87.pdf TORONTO, ONTARIO - March 30, 2016 -- Merus Labs International Inc. ("Merus" or the "Company") reported today the results ...
04/04/16 11:00 AMMarch 7, 2016 Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi - [at noodls] - 6e0a6d4e-4b83-4f5e-ab85-0c8b549cb4df.pdf TORONTO, ONATRIO - March 7, 2016 - Merus Labs International Inc. ("Merus" or the "Company") announced today that it ...
02/02/16 01:12 PMMerus Labs Int'l (MSLI) to Acquire Three Cardiovascular Products from UCB in EUR 92M Deal - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Merus Labs International Inc. (Nasdaq: MSLI] announced that it has entered into an agreement with UCB to acquire rights to Elantan, Isoket and Deponit in Europe and ...
02/01/16 01:55 PM2:55 pm Merus Labs to acquire UCB's rights to Elantan, Isoket and Deponit in Europe and select other markets for EUR92 mln; updates FY16 EBITDA guidance (shares halted) -
01/05/16 12:04 PMMERUS LABS INTERNATIONAL INC. Financials -
07/10/15 06:00 AMMerus Labs Announces Filing of Preliminary Base Shelf Prospectus - [PR Newswire] - TORONTO, July 10, 2015 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI], announced today that it has filed a preliminary short form base shelf prospectus with the securities commissions in all provinces in Canada, other than Quebec, Nova Scotia and Newfoundland, and a corresponding shelf registration statement on Form F-10 with the U.S. Securities and Exchange Commission (the "SEC") under the U.S./Canada Multijurisdictional Disclosure System. The base shelf prospectus and corresponding shelf registration statement, when made final or effective, will allow Merus to offer up to $250,000,000 of common shares, warrants, preferred shares, subscription receipts and units, or any combination thereof, from time to time over a 25-month period. The specific terms of any offering of securities will be set forth in a shelf prospectus supplement.
06/03/15 03:00 PMMerus Labs Provides an Update on German Reimbursement Review - [CNW Group] - Merus Labs Provides an Update on German Reimbursement Review

Social

About Merus Labs International

Merus Labs International logoMerus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women's health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MSLI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.32
  • 50 Day Moving Average: $1.27
  • 200 Day Moving Average: $1.38
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $135.43M
  • Beta: 1.45
  • Current Year EPS Consensus Estimate: $-0.03 EPS
  • Next Year EPS Consensus Estimate: $0.03 EPS
Additional Links:
Merus Labs International (NASDAQ:MSLI) Chart for Wednesday, July, 27, 2016